Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM90EO3)

Drug Name

ABBV-621 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Haematological malignancy	2B33.Y	Phase 1	[1]
Hematologic tumour	2B33.Y	Phase 1	[2]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting TNF related apoptosis inducing ligand (TNFSF10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ad5-TRAIL	DM2UMGE	Prostate cancer	2C82.0	Phase 1	[4]
DA-3607	DM4JG0B	Brain cancer	2A00	Phase 1	[5]
Nimesulide	DMR1NMD	Metastatic colorectal cancer	2B91	Terminated	[6]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
TNF related apoptosis inducing ligand (TNFSF10)	TTA5MS9	TNF10_HUMAN	Agonist	[3]

------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	ClinicalTrials.gov (NCT03082209) A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies. U.S. National Institutes of Health.
3	Clinical pipeline report, company report or official report of AbbVie.
4	Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors. Cancer Gene Ther. 2006 Jun;13(6):628-32.
5	Cancer gene therapy using a novel secretable trimeric TRAIL. Gene Ther. 2006 Feb;13(4):330-8.
6	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.